科创成长层要上新！科创成长层新注册企业发行准备就绪 禾元生物启动发行将成新成员

Core Viewpoint - The issuance of new registered companies in the Sci-Tech Innovation Growth Layer is ready, with Wuhan Heyuan Biotechnology Co., Ltd. initiating its issuance, marking a significant step in the "1+6" reform of the Sci-Tech Innovation Board [1][3]. Group 1: Company Overview - Heyuan Biotechnology is the first company to start the issuance process after the resumption of the fifth set of standards for the Sci-Tech Innovation Board [4]. - The company has developed a globally pioneering "rice-derived blood" technology, supported by the national "Major New Drug Creation" program [4]. - Heyuan's self-developed innovative drug, recombinant human albumin injection (from rice), was approved for market launch in July, aiming to reduce China's long-term reliance on imported human serum albumin [4]. Group 2: Market Context - The issuance of Heyuan Biotechnology reflects the implementation of the "1+6" reform, enhancing the system's inclusiveness and adaptability for high-quality technology enterprises [4]. - The company is the first to adopt differentiated lock-up and allocation arrangements for offline issuance, with a minimum lock-up ratio of 40% for offline investors [4]. - The Shanghai Stock Exchange has revised its issuance and underwriting rules, allowing unprofitable companies to use agreed lock-up methods, encouraging professional institutions to play a larger role in new stock pricing [5]. Group 3: Industry Developments - Since the announcement of the "1+6" reform policy in June, 15 companies have applied for IPOs on the Sci-Tech Innovation Board, including four unprofitable companies [6]. - Three unprofitable companies have already received IPO registration approval, with two of them under the fifth set of standards [7]. - The Shanghai Stock Exchange has completed system tests for the new registered companies in the Sci-Tech Innovation Growth Layer, with 5 million investors having opened trading permissions for this layer [7].